More than baby steps: Perspectives on pediatric translational research

Science Translational Medicine

Volumn 1, Issue 2, 2009, Pages

  Connor, Edward ^a   Lombardi, Donald ^b   Van Den Anker, John ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b Institute for Pediatric Innovation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; HUMAN; MEDICAL RESEARCH; PEDIATRICS; UNITED STATES;

BIOMEDICAL RESEARCH; CHILD; HUMANS; PEDIATRICS; UNITED STATES;

EID: 77954682721     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000152     Document Type: Note

References (8)

1. C.-P. Milne, in Pediatric Drug Development: Concepts and Applications, A. E. Mulberg, S. A. Silber, J. van den Anker, Eds. (Wiley, New Jersey, 2009), pp. 21-38.
2. C. Vanchieri, A. Stith Butler, A. Knutsen, Addressing the Barriers of Pediatric Drug Development: Workshop Summary (Forum on Drug Discovery, Development, and Translation, Institute of Medicine, Washington, DC, 2008).
3. J. A. DiMasi, R. W. Hansen, H. G. Grabowski, The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
4. Tufts Center for the Study of Drug Development, Impact and Outlook Reports (http://csdd.tufts.edu/InfoServices/ Publications.asp).
5. U.S. Food and Drug Administration, Pediatric Drug Development (www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867. htm).
6. T. Yokota, S. Takeda, Q. L. Lu, T. A. Partridge, A. Nakamura, E. P. Hoffman, A renaissance for antisense oligonucleotide drugs in neurology: Exon skipping breaks new ground. Arch. Neurol. 66, 32-38 (2009).
7. S. Hirschfeld, P.T.C. Ho, M. Smith, R. Pazdur, Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives. J. Clin. Oncol. 21, 1066-1073 (2003).
8. J. Boklan, Little patients, losing patience: Pediatric cancer drug development. Mol. Cancer Ther. 5, 1905-1908 (2006).